Safety Study of rhASM Enzyme Replacement Therapy in Adults With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)

This study has been terminated.
(Terminated by sponsor - Single dose safety objective achieved.)
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company ) Identifier:
First received: December 11, 2006
Last updated: March 17, 2015
Last verified: March 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: April 2009
  Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)